Oncolys BioPharma Inc. announced that it has received notice from Transposon Therapeutics Inc. licensee of OBP-601 (Censavudine, TPN-101), that the first patient has been enrolled in the Phase IIa, double-blind, placebo-controlled study of patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Degeneration (FTD). The study will be conducted in multiple centers in the United States and Europe. In addition, Transposon continues to enroll patients with Progressive Supranuclear Palsy (PSP) in a Phase IIa, double-blind, placebo-controlled study conducted in the US.

PSP, ALS and FTD are rare but devastating neurodegenerative diseases for which new treatments are eagerly awaited. The ongoing Phase IIa studies will evaluate the effect of OBP-601 on biomarkers of target engagement, disease and neuroinflammation.